Abstract
Immune checkpoint inhibitors (ICIs) are an essential component of metastatic non-small cell lung cancer (NSCLC) treatment. Metastatic NSCLC patients frequently develop brain metastases requiring treatment with CNS radiation therapy (CNS-RT). Prospective data on safety and outcomes with overlapping immunotherapy and CNS-RT is lacking. Retrospective studies have reported safety in this population with no increased risk of radiographic events of hemorrhage or radionecrosis. We completed a retrospective review to evaluate rates of clinically significant CNS adverse events (CNS-AEs) and OS in those receiving CNS-RT with and without concurrent ICI use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
